Aminolevulinate Delta Dehydratase (ALAD) Antibody

Product specifications

Primary Antibodies

Aminolevulinate Delta Dehydratase (ALAD)

Mouse

Human

WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.

Monoclonal

Unconjugated

Purified by Protein A and Protein G affinity chromatography.

1 ml

Liquid

WB, IHC, IF/ICC

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Please enquire.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

ALADH,Porphobilinogen synthase,ALA dehydratase

Antibody anti-ALAD

RUO

Descripción

Aminolevulinate Delta Dehydratase (ALAD) is a key enzyme in the heme biosynthesis pathway, catalyzing the condensation of two molecules of aminolevulinic acid (ALA) into porphobilinogen (PBG), a precursor to heme. ALAD is predominantly expressed in the liver and bone marrow, where heme production is critical for hemoglobin synthesis in red blood cells and for cytochrome function in metabolic processes. The enzyme requires zinc as a cofactor for its activity, and mutations or environmental inhibitors, such as lead, can impair ALAD function, leading to disorders such as porphyria or anemia. Lead poisoning inhibits ALAD by displacing zinc, resulting in the accumulation of ALA and associated neurotoxic effects. ALAD mutations can also cause ALAD porphyria, a rare genetic disorder marked by abdominal pain, neuropsychiatric symptoms, and photosensitivity. ALAD is a target of interest for understanding and mitigating lead toxicity and heme-related metabolic disorders.

Related Products

Human ALAD (Delta-aminolevulinic acid dehydRatase) ELISA Kit

Ver Producto

Mouse ALAD (Aminolevulinate Delta DehydRatase) ELISA Kit

Ver Producto

Recombinant Human ALAD

Ver Producto